NCT06331910|UnknownPhase 4
Efficacy and Safety of Topical Insulin for Neurotrophic Corneal Ulcers
Topical Insulin in Treatment of Neurotrophic Corneal Ulcer,Efficacy And Safety
Loading search results
Topical Insulin in Treatment of Neurotrophic Corneal Ulcer,Efficacy And Safety
Sponsor study identifier
interventional
14
0 countries
N/A
Study Start
April 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
April 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To evaluate Safety and efficacy of topical insulin in treatment of neurotrophic corneal ulcers
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 15, 2024
Actual (reported)March 26, 2024
Actual (reported)April 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
April 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Decrease in ulcer size and the increase in visual acuity .
To evaluate the effect of topical insulin eye drops in treatment of neurotrophic corneal ulcer.
baseline
Insulin eye drops deliver insulin directly to the cornea, They exploit insulin's ability to stimulate cell growth, potentially reducing healing time with minimal side effects.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Wang AL, Weinlander E, Metcalf BM, Barney NP, Gamm DM, Nehls SM, Struck MC. Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers. Cornea. 2017 Nov;36(11):1426-1428. doi: 10.1097/ICO.0000000000001297.
Shanley LJ, McCaig CD, Forrester JV, Zhao M. Insulin, not leptin, promotes in vitro cell migration to heal monolayer wounds in human corneal epithelium. Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1088-94. doi: 10.1167/iovs.03-1064.
First Submitted
March 15, 2024
First Posted
March 26, 2024
Study Start
April 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
April 1, 2025
Contact the study team to confirm eligibility.
Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch Ophthalmol. 2007 Aug;125(8):1082-8. doi: 10.1001/archopht.125.8.1082.
Nishida T, Yanai R. Advances in treatment for neurotrophic keratopathy. Curr Opin Ophthalmol. 2009 Jul;20(4):276-81. doi: 10.1097/icu.0b013e32832b758f.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 26, 2024
Record last verified: 2024-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: